Radioimmunotherapy-based treatment of cancer
Iranian Journal of Nuclear Medicine. 2012; 20 (1): 45-53
in English
| IMEMR
| ID: emr-155508
ABSTRACT
The principle of cancer immunotherapy includes various methods of manipulations to influence immune responses against tumors in both humans and animals. This advanced technology of hybridoma production provided the necessary skills to efficiently produce highly specific monoclonal antibodies [mAb]. Radioactively-tagged antibodies which are applied in radioimmunotherapy [RIT], can target adjacent cells and may not require immune function. This study highlights the mechanism and the effect of action of radioimmunotherapic agents, especially two applied agents including [90]Yibritumomab tiuxetan and [131]I-tositumomab that are approved by Food and Drug Administration [FDA] for treatment of some cancers
Search on Google
Index:
IMEMR (Eastern Mediterranean)
Main subject:
Yttrium Radioisotopes
/
Antibodies, Monoclonal
/
Neoplasms
Limits:
Humans
Language:
English
Journal:
Iran. J. Nucl. Med.
Year:
2012
Similar
MEDLINE
...
LILACS
LIS